![]() |
|||||||
|
Fusion Protein:CDC42BPB-RGS6 |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: CDC42BPB-RGS6 | FusionPDB ID: 14858 | FusionGDB2.0 ID: 14858 | Hgene | Tgene | Gene symbol | CDC42BPB | RGS6 | Gene ID | 9578 | 9628 |
Gene name | CDC42 binding protein kinase beta | regulator of G protein signaling 6 | |
Synonyms | MRCKB | GAP|HA117|S914 | |
Cytomap | 14q32.32 | 14q24.2 | |
Type of gene | protein-coding | protein-coding | |
Description | serine/threonine-protein kinase MRCK betaCDC42 binding protein kinase beta (DMPK-like)CDC42BP-betaDMPK-like betaMRCK betamyotonic dystrophy kinase-related CDC42-binding kinase betamyotonic dystrophy protein kinase-like beta | regulator of G-protein signaling 6regulator of G-protein signalling 6 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | Q9Y5S2 Main function of 5'-partner protein: FUNCTION: Serine/threonine-protein kinase which is an important downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization and cell migration. Regulates actin cytoskeletal reorganization via phosphorylation of PPP1R12C and MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A and LURAP1, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the lamellipodium resulting in its activation and subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation (By similarity). {ECO:0000250|UniProtKB:Q7TT50, ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21457715, ECO:0000269|PubMed:21949762}. | . | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000361246, | ENST00000343854, ENST00000355512, ENST00000402788, ENST00000404301, ENST00000406236, ENST00000407322, ENST00000434263, ENST00000553690, ENST00000554782, ENST00000556437, ENST00000553525, ENST00000553530, ENST00000555571, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 17 X 16 X 10=2720 | 11 X 10 X 6=660 |
# samples | 19 | 13 | |
** MAII score | log2(19/2720*10)=-3.83953532780675 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(13/660*10)=-2.34395440121736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: CDC42BPB [Title/Abstract] AND RGS6 [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: CDC42BPB [Title/Abstract] AND RGS6 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CDC42BPB(103449893)-RGS6(73029125), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. | CDC42BPB-RGS6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CDC42BPB-RGS6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CDC42BPB-RGS6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CDC42BPB-RGS6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CDC42BPB-RGS6 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. CDC42BPB-RGS6 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. CDC42BPB-RGS6 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. CDC42BPB-RGS6 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. CDC42BPB-RGS6 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CDC42BPB | GO:0006468 | protein phosphorylation | 21949762 |
Tgene | RGS6 | GO:0043547 | positive regulation of GTPase activity | 10521509 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr14:103449893/chr14:73029125) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000361246 | CDC42BPB | chr14 | 103449893 | - | ENST00000553525 | RGS6 | chr14 | 73029125 | + | 1240 | 1180 | 184 | 1230 | 348 |
ENST00000361246 | CDC42BPB | chr14 | 103449893 | - | ENST00000555571 | RGS6 | chr14 | 73029125 | + | 1231 | 1180 | 184 | 1230 | 349 |
ENST00000361246 | CDC42BPB | chr14 | 103449893 | - | ENST00000553530 | RGS6 | chr14 | 73029125 | + | 2710 | 1180 | 184 | 1230 | 348 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000361246 | ENST00000553525 | CDC42BPB | chr14 | 103449893 | - | RGS6 | chr14 | 73029125 | + | 0.001554664 | 0.99844533 |
ENST00000361246 | ENST00000555571 | CDC42BPB | chr14 | 103449893 | - | RGS6 | chr14 | 73029125 | + | 0.001531888 | 0.9984681 |
ENST00000361246 | ENST00000553530 | CDC42BPB | chr14 | 103449893 | - | RGS6 | chr14 | 73029125 | + | 0.000901498 | 0.99909854 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for CDC42BPB-RGS6 |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
CDC42BPB | chr14 | 103449893 | RGS6 | chr14 | 73029125 | 1180 | 332 | SLVETYGKIMNHEGKSLAGKRLTGLM |
Top |
Potential FusionNeoAntigen Information of CDC42BPB-RGS6 in HLA I |
![]() |
CDC42BPB-RGS6_103449893_73029125.msa |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | HLA-C03:67 | IMNHEGKSL | 0.9463 | 0.9781 | 8 | 17 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | HLA-B15:73 | IMNHEGKSL | 0.8736 | 0.8355 | 8 | 17 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | HLA-B15:30 | IMNHEGKSL | 0.795 | 0.8509 | 8 | 17 |
Top |
Potential FusionNeoAntigen Information of CDC42BPB-RGS6 in HLA II |
![]() |
CDC42BPB-RGS6_103449893_73029125.msa |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-0443 | LVETYGKIMNHEGKS | 1 | 16 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-0447 | LVETYGKIMNHEGKS | 1 | 16 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-0447 | VETYGKIMNHEGKSL | 2 | 17 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-0454 | LVETYGKIMNHEGKS | 1 | 16 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-0454 | VETYGKIMNHEGKSL | 2 | 17 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-0475 | LVETYGKIMNHEGKS | 1 | 16 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-1504 | YGKIMNHEGKSLAGK | 5 | 20 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-1505 | YGKIMNHEGKSLAGK | 5 | 20 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-1510 | YGKIMNHEGKSLAGK | 5 | 20 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-1510 | TYGKIMNHEGKSLAG | 4 | 19 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-1510 | GKIMNHEGKSLAGKR | 6 | 21 |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 | DRB1-1537 | YGKIMNHEGKSLAGK | 5 | 20 |
Top |
Fusion breakpoint peptide structures of CDC42BPB-RGS6 |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
2898 | GKIMNHEGKSLAGK | CDC42BPB | RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1180 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CDC42BPB-RGS6 |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
HLA-B14:02 | 3BVN | 2898 | GKIMNHEGKSLAGK | -7.9962 | -8.1096 |
HLA-B14:02 | 3BVN | 2898 | GKIMNHEGKSLAGK | -5.70842 | -6.74372 |
HLA-B52:01 | 3W39 | 2898 | GKIMNHEGKSLAGK | -6.83737 | -6.95077 |
HLA-B52:01 | 3W39 | 2898 | GKIMNHEGKSLAGK | -4.4836 | -5.5189 |
HLA-A11:01 | 4UQ2 | 2898 | GKIMNHEGKSLAGK | -10.0067 | -10.1201 |
HLA-A11:01 | 4UQ2 | 2898 | GKIMNHEGKSLAGK | -9.03915 | -10.0745 |
HLA-A24:02 | 5HGA | 2898 | GKIMNHEGKSLAGK | -6.56204 | -6.67544 |
HLA-A24:02 | 5HGA | 2898 | GKIMNHEGKSLAGK | -5.42271 | -6.45801 |
HLA-B44:05 | 3DX8 | 2898 | GKIMNHEGKSLAGK | -7.85648 | -8.89178 |
HLA-B44:05 | 3DX8 | 2898 | GKIMNHEGKSLAGK | -5.3978 | -5.5112 |
HLA-A02:01 | 6TDR | 2898 | GKIMNHEGKSLAGK | -3.37154 | -4.40684 |
Top |
Vaccine Design for the FusionNeoAntigens of CDC42BPB-RGS6 |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 8 | 17 | IMNHEGKSL | ATCATGAACCATGAAGGAAAGTCGCTG |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 1 | 16 | LVETYGKIMNHEGKS | CTCGTGGAGACCTATGGGAAGATCATGAACCATGAAGGAAAGTCG |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 2 | 17 | VETYGKIMNHEGKSL | GTGGAGACCTATGGGAAGATCATGAACCATGAAGGAAAGTCGCTG |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 4 | 19 | TYGKIMNHEGKSLAG | ACCTATGGGAAGATCATGAACCATGAAGGAAAGTCGCTGGCGGGC |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 5 | 20 | YGKIMNHEGKSLAGK | TATGGGAAGATCATGAACCATGAAGGAAAGTCGCTGGCGGGCAAG |
CDC42BPB-RGS6 | chr14 | 103449893 | chr14 | 73029125 | 6 | 21 | GKIMNHEGKSLAGKR | GGGAAGATCATGAACCATGAAGGAAAGTCGCTGGCGGGCAAGCGC |
Top |
Information of the samples that have these potential fusion neoantigens of CDC42BPB-RGS6 |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
SKCM | CDC42BPB-RGS6 | chr14 | 103449893 | ENST00000361246 | chr14 | 73029125 | ENST00000553525 | TCGA-FW-A5DX-01A |
Top |
Potential target of CAR-T therapy development for CDC42BPB-RGS6 |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to CDC42BPB-RGS6 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to CDC42BPB-RGS6 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |